North America CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others), Country (U.S, Canada and Mexico) Industry Trends and Forecast to 2028
Market Analysis and Insights: North America CAR-T Cell Therapy Treatment Market
The CAR-T cell therapy treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 29.9% in the forecast period of 2021 to 2028 and is expected to reach USD 5,692.88 million by 2028. Increase in usage of CAR-T cell therapy for the treatment of cancer and infectious disease acting as driver for the CAR-T cell therapy treatment market growth.
CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein.
The rise in awareness about immunotherapies led the people to come across several kinds of CAR-T therapies and their effectiveness and hence acts as driver for the CAR-T cell therapy treatment market. Adverse side effects of therapies restricts some population to opt for such treatment which impacts the product value and hence acts as restrain for the CAR-T cell therapy treatment market growth. Presence of pipeline products suggest that market players are constantly engaged in manufacturing of innovative medicines thus acts as opportunity for the CAR-T cell therapy treatment market. Long approval time for immunotherapies restrict the product manufacturer to earn potential benefit in the market and impacts the overall market size hence acts as challenge for the CAR-T cell therapy treatment market growth.
The CAR-T cell therapy treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America CAR-T Cell Therapy Treatment Market Scope and Market Size
The CAR-T cell therapy treatment market is segmented on the basis of the product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells. In 2021, autologous CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the drugs approved for CAR-T cell therapy are autologous in nature.
- On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells. In 2021, second generation CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the approved therapies are second generation based structure.
- On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. In 2021, antigens on hematologic malignancies segment is expected to dominate the CAR-T cell therapy treatment market because drugs approved for CAR-T cell therapy are majorly used for hematologic malignancies and ongoing extensive research development.
- On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others. In 2021, yescarta segment is expected to dominate the CAR-T cell therapy treatment market because yescarta is the first approved CAR-T cell therapy for oncology therapeutic class.
- On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. In 2021, hematological malignancies segment is expected to dominate the CAR-T cell therapy treatment market because yescarta accounts the major revenue in the market and the follicular lymphoma is the major indication for yescarta.
- On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. In 2021, hospitals segment is dominating the CAR-T cell therapy treatment market because CAR-T cell therapy required highly trained professionals with advanced technology laboratories.
CAR-T Cell Therapy Treatment Market Country Level Analysis
The CAR-T cell therapy treatment market is analyzed and market size information is provided on based on the country, product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel as referenced above.
The countries covered in the North America CAR-T cell therapy treatment market report are the U.S, Mexico, and Canada
The U.S. is dominating in the North America CAR-T cell therapy treatment market and is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing healthcare expenditure and well-established healthcare infrastructure for the autologous CAR-T cells segment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Awareness about Immunotherapies is boosting the CAR-T Cell Therapy Treatment Market Growth
The CAR-T cell therapy treatment market also provides you with detailed market analysis for every country growth in CAR-T cell therapy treatment industry with CAR-T cell therapy treatment sales, impact of advancement in the CAR-T cell therapy treatment technology and changes in regulatory scenarios with their support for the CAR-T cell therapy treatment market. The data is available for historic period 2011 to 2019.
Competitive Landscape and CAR-T Cell Therapy Treatment Market Share Analysis
The CAR-T cell therapy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to CAR-T cell therapy treatment market. .
The major companies which are dealing in the CAR-T cell therapy treatment are Atara Biotherapeutics, Inc., Amgen Inc., Bellicum Phamaceuticals, Inc., bluebird bio, inc., Adaptimmune Therapeutics plc., Bristol-Myers Squibb Company, Xyphos (A Subsidiary of Astellas Pharma Inc.), Johnson & Johnson Services, Inc., BioAtla Inc., Novartis AG, Kite Pharma (A Subsidiary of Gilead Sciences, Inc.), Aurora Biopharma, Tmunity Therapeutics, Cartherics Pty ltd, Ziopharm Oncology, Inc., Cellectis, Mustang Bio, Sorrento Therapeutics, Inc., TC BIOPHARM, Celyad Oncology, Tessa Therapeutics Ltd, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the CAR-T cell therapy treatment market.
For instance,
- In December 2020, Atara Biotherapeutics, Inc. went under collaboration with Bayer AG for development of mesothelin-targeted CAR T-cell therapies for solid tumors. As per the agreement, the company is highly focused on the development of ATA2271 in order to treat malignant pleural mesothelioma and non-small-cell lung cancer. This collaboration accelerated the company’s research and development for ATA2271 and allowed it to become the leading allogeneic CAR-T cell therapy manufacturer.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company market in the CAR-T cell therapy treatment market which also provides the benefit for organization to improve their offering for CAR-T cell therapy treatment.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET PRODUCT COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN USAGE OF CAR-T CELL THERAPY FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
7.1.2 INCREASING PREVALENCE OF CANCER
7.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES
7.1.4 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
7.1.5 ADOPTION OF CAR-T CELL THERAPY TREATMENT IN EMERGING MARKETS
7.2 RESTRAINTS
7.2.1 ADVERSE SIDE EFFECTS OF THERAPIES
7.2.2 HIGH COST ASSOCIATED WITH THERAPIES
7.2.3 LOGISTIC CHALLENGE ASSOCIATED WITH CAR-T THERAPIES
7.2.4 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
7.3 OPPORTUNITIES
7.3.1 PRESENCE OF PIPELINE PRODUCTS
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
7.4 CHALLENGES
7.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES
7.4.2 LACK OF SKILLED PROFESSIONALS
8 IMPACT OF COVID-19 ON NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION FOR MANUFACTURERS
8.5 CONCLUSION
9 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 AUTOLOGOUS CAR-T CELLS
9.3 ALLOGENEIC CAR-T CELLS
10 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE
10.1 OVERVIEW
10.2 FIRST GENERATION CAR-T CELLS
10.3 SECOND GENERATION CAR-T CELLS
10.4 THIRD GENERATION CAR-T CELLS
10.5 FOURTH GENERATION CAR-T CELLS
11 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS
11.1 OVERVIEW
11.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES
11.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19)
11.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30)
11.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22)
11.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20)
11.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33)
11.3 ANTIGENS ON SOLID TUMORS
11.3.1 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER-2)
11.3.2 EPIDERMAL GROWTH FACTOR RECEPTORS VARIANT III (EGFRV-III)
11.3.3 MESOTHELIN (MSLN)
11.3.4 PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
11.3.5 INTERLEUKIN-13RA2 (IL13RA2)
11.3.6 DISIALOGANGLIOSIDE 2 (GD2)
11.3.7 GLYPICAN-3 (GPC3)
11.3.8 OTHERS
11.4 OTHERS
12 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND
12.1 OVERVIEW
12.2 YESCARTA
12.3 KYMRIAH
12.4 TECARTUS
12.5 OTHERS
13 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION
13.1 OVERVIEW
13.2 FOLLICULAR LYMPHOMA
13.3 DIFFUSE LARGE B-CELL LYMPHOMA
13.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
13.5 MANTLE CELL LYMPHOMA
13.6 MULTIPLE MYELOMA
13.7 HEMATOLOGIC MALIGNANCIES
13.7.1 LEUKEMIA
13.7.2 LYMPHOMA
13.7.3 MYELOMA
13.7.4 OTHERS
13.8 LUNG CANCER
13.9 CHRONIC LYMPHOCYTIC LEUKEMIA
13.1 GASTRIC CANCER
13.11 PANCREATIC CANCER
13.12 BREAST CANCER
13.13 OTHERS
14 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 OTHERS
15 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 OTHERS
16 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 KITE PHARMA (A SUBSIDIARY OF GILEAD SCIENCES, INC.)
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 NOVARTIS AG
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 ABBVIE INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENTS
19.4 ADAPTIMMUNE THERAPEUTICS PLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 AMGEN INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PIPELINE PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ATARA BIOTHERAPEUTICS, INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PIPELINE PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENTS
19.7 AURORA BIOPHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 PIPELINE PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AUTOLUS
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 BELLICUM PHAMACEUTICALS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 BIOATLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 BLUEBIRD BIO, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 BRISTOL-MYERS SQUIBB COMPANY
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 CARINA BIOTECH
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 CARTHERICS PTY LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 CARTESIAN THERAPEUTICS, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PIPELINE PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 CELLECTIS SA
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 CELYAD ONCOLOGY SA
19.17.1 COMPANY SNAPSHOT
19.17.2 PIPELINE PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 JOHNSON & JOHNSON SERVICES, INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 SORRENTO THERAPEUTICS, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PIPELINE PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 TC BIOPHARM LIMITED
19.20.1 COMPANY SNAPSHOT
19.20.2 PIPELINE PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 TESSA THERAPEUTICS LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 PIPELINE PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 TMUNITY THERAPEUTICS
19.22.1 COMPANY SNAPSHOT
19.22.2 PIPELINE PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 MUSTANG BIO
19.23.1 COMPANY SNAPSHOT
19.23.2 PIPELINE PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 XYPHOS (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
19.24.1 COMPANY SNAPSHOT
19.24.2 REVENUE ANALYSIS
19.24.3 PIPELINE PRODUCT PORTFOLIO
19.24.4 RECENT DEVELOPMENTS
19.25 ZIOPHARM ONCOLOGY, INC.
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 BELOW PROVIDED ARE THE ALTERNATIVE CHEMOTHERAPIES OF CAR-T CELL THERAPY:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET, BY MOLECULE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA AUTOLOGOUS CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 6 NORTH AMERICA ALLOGENEIC CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET, BY STRUCTURE, 2019-2028 (USD MILLION)
CELYAD IS ENGAGED IN THE MANUFACTURING OF CYAD-211, A FIRST GENERATION CAR-T CELL THERAPY EXPRESSING BCMA TARGETING CHIMERIC ANTIGEN RECEPTOR WHICH INTERFERES WITH THE EXPRESSION OF THE CD3Ζ OF T CELL RECEPTOR COMPLEX.
TABLE 8 NORTH AMERICA FIRST GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA SECOND GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON HEMATOLOGIC MALIGNANCIES, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 16 NORTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON SOLID TUMORS, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 18 NORTH AMERICA YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 19 NORTH AMERICA YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 20 NORTH AMERICA KYMRIAH IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 21 NORTH AMERICA TECARTUS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 22 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 23 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA FOLLICULAR LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 25 NORTH AMERICA DIFFUSE LARGE B-CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 26 NORTH AMERICA ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 27 NORTH AMERICA MANTLE CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 28 NORTH AMERICA MULTIPLE MYELOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 29 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 30 NORTH AMERICA HEMATOLOGIC MALIGNANCIES ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA LUNG CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 32 NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 33 NORTH AMERICA GASTRIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 34 NORTH AMERICA PANCREATIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 35 NORTH AMERICA BREAST CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 39 NORTH AMERICA SPECIALTY CLINICS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA HOSPITAL PHARMACY IN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2028 (USD MILLION)
TABLE 43 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 44 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 56 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 57 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 58 U.S ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 59 U.S ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 60 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 61 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 U.S HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 67 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 68 CANADA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 69 CANADA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 70 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 71 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 CANADA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 74 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 76 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 77 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 78 MEXICO ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 79 MEXICO ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 80 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 81 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 MEXICO HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: MARKET PRODUCT COVERAGE GRID
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 AUTOLOGUS CAR-T CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET
FIGURE 15 NEW CANCER CASES WORLDWIDE, (2018)
FIGURE 16 NORTH AMERICA CANCER INCIDENCE (2018)
FIGURE 17 CANCER DEATH BY TYPE (IN MILLION), WORLD, 2017
FIGURE 18 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2021
FIGURE 19 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2019-2028 (USD MILLION)
FIGURE 20 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 21 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 22 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2021
FIGURE 23 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2019-2028 (USD MILLION)
FIGURE 24 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2021-2028)
FIGURE 25 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2021
FIGURE 27 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
FIGURE 28 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, CAGR (2021-2028)
FIGURE 29 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, LIFELINE CURVE
FIGURE 30 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020
FIGURE 31 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020-2028 (USD MILLION)
FIGURE 32 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2020-2028)
FIGURE 33 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE
FIGURE 34 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020
FIGURE 35 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020-2028 (USD MILLION)
FIGURE 36 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, CAGR (2020-2028)
FIGURE 37 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 38 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020
FIGURE 39 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 40 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 41 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 43 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 44 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 45 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 47 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 48 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 49 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 50 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028)
FIGURE 51 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
